Precision Antibody, a leader in custom monoclonal antibody development, is proud to announce its participation and scientific presentations at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.
Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.
Precision Antibody, a leading provider of custom monoclonal antibody development services, is pleased to announce its participation in Antibody Engineering & Therapeutics Event, on December 14–17, 2025, at the Marriott Marquis San Diego, California.
Precision Antibody will showcase its expertise in biomarker antibody development at the 20 Drug Discovery Strategic Summit, Nov 19–20, 2025, in Amsterdam, highlighting its high-quality monoclonal antibody solutions for drug discovery and diagnostics.
Precision Antibody will showcase its biomarker antibody expertise at the World ADC Conference 2025 in San Diego, highlighting its role in advancing ADC and cancer biomarker research through high-quality monoclonal antibody development.
Precision Antibody will showcase its high-affinity, epitope-rich, and fully functional antibody development technologies at AET Asia 2025 in Kyoto, highlighting innovations that accelerate discovery and therapeutic antibody programs worldwide.
Precision Antibody will present its fully human monoclonal antibody development platform at the 19th Drug Discovery Strategic Summit, highlighting rapid, royalty-free antibody solutions advancing cancer research and drug discovery.
Precision Antibody will attend the World CDx Summit 2025 in Boston, showcasing its expertise in biomarker antibody development and contributions to NCI’s CPTC program, reinforcing its role in advancing precision medicine.
Precision Antibody will attend Interphex Regenerative Medicine 2025 in Tokyo from July 9–11. Dr. Jun Hayashi will present on fully human antibody development, highlighting the company’s commitment to global collaboration and therapeutic innovation.
Precision Antibody will attend Antibody Engineering & Therapeutics Europe, June 10–12, 2025, in Basel, to showcase its high-specificity monoclonal antibody solutions for accelerating therapeutic discovery.
Precision Antibody CEO Dr. Ginette Serrero to speak at the 23rd BioPharma Drug Discovery Nexus, May 7–8 in San Francisco, on advancing monoclonal antibody development for early-stage drug discovery.
Precision Antibody will showcase its cutting-edge custom antibody solutions at INTERPHEX Week Osaka 2025, focusing on regenerative medicine, therapeutics, and industry collaborations.